BIVI BioVie Inc.
USHealthcareAs of 2026-07-09 16:00
Why BIVI matters now
BioVie Inc. (BIVI) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.24 with +2.75% on the session and $16.9M in market capitalization; recent performance reads 1-month +34.35% and YTD +51.72%.
The latest financial table shown here is Q3 2026, with revenue of $0.00, net income of $-5.3M, and EPS of $-0.70. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -154.5%.
The latest indexable market news headline is "Did BioVie Inc. Insiders Breach their Fiduciary Duties to Shareholders?" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Lang James Paul filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.85
P/S
0.00
EV/EBITDA
-0.02
DCF Value
$12.85
FCF Yield
-154.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-101.1%
ROA
-113.7%
ROIC
-129.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $0.00 | $-5.3M | $-0.70 |
| Q2 2026 | $0.00 | $-6.1M | $-0.77 |
| Q1 2026 | $0.00 | $-5.1M | $-0.98 |
| Q4 2025 | $0.00 | $-3.5M | $-1.82 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.67
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease. Further preclinical investigations are underway for NE3107, exploring its potential applications in treating multiple myeloma and prostate cancer. Established in 2013, the company adopted its current name, BioVie Inc., in July 2016, having previously operated as NanoAntibiotics, Inc. Its corporate headquarters are situated in Carson City, Nevada.